New immunotherapy combo targets Hard-to-Treat cancers
NCT ID NCT06680739
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing two immunotherapy drugs, durvalumab and tremelimumab, alone or together, in 60 people with colorectal or endometrial cancer. The goal is to see if these drugs can shrink tumors or slow cancer growth. The study focuses on patients with different genetic types of tumors (MSI-high and MSS) to better understand who might benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab and tremelimumab (immunotherapy drugs)
- What this could lead to
- If successful, this could point toward a more effective immunotherapy approach for hard-to-treat colorectal and endometrial cancers.
- What could go wrong
- This is a small, early-phase trial (60 participants) and may not show strong results. Immunotherapy can cause immune-related side effects, and not all patients respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vall d'Hebron Institute of Oncology
RECRUITINGBarcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a smart digital program restore sleep for cancer survivors?